Form 15-12G AVEO PHARMACEUTICALS,
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-34655
AVEO Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
30 Winter Street
Boston, Massachusetts 02108
(857) 400-0101
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, Par Value $0.001 Per Share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) | ☒ | |
Rule 12g-4(a)(2) | ☐ | |
Rule 12h-3(b)(1)(i) | ☒ | |
Rule 12h-3(b)(1)(ii) | ☐ | |
Rule 15d-6 | ☐ | |
Rule 15d-22(b) | ☐ |
Approximate number of holders of record as of the certification or notice date: One (1)
Pursuant to the requirements of the Securities Exchange Act of 1934, AVEO Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
AVEO PHARMACEUTICALS, INC. | ||||||
Date: January 30, 2023 | By: | /s/ Michael Bailey | ||||
Name: | Michael Bailey | |||||
Title: | President and Chief Executive Officer |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures
- Titan Logix Corp. Reports its Fiscal 2024 Second Quarter Financial Results
- Fourth Update on Ongoing Matters at AnalytixInsight
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!